■在过去十年中,针对转移性激素敏感(mHSPC)和去势抵抗(mCRPC)前列腺癌的新型全身疗法获得批准,患者可能会接受几种治疗线。然而,这些治疗方法的使用正在发生变化。我们调查了不同治疗系的当代治疗趋势和无进展(PFS)和总体(OS)生存率。
■依靠我们的机构三级护理数据库,我们确定了mHSPC和mCRPC患者。主要结果包括过去十年中的治疗变化(估计的年度变化百分比[EAPC]),以及不同mHSPC和mCRPC治疗线的PFS和OS。
■在1098名转移性患者中,中位年龄为70岁,中位年龄为2个系统治疗线.对于2013年至2023年的一线mCRPC,雄激素剥夺单药治疗(ADT)单药治疗的使用率从31%显着下降至0%(EAPC-38.3%,p<0.001),而化疗从16.7%增加到33.3%(EAPC:+10.1%,p<0.001)。mHSPC患者的PFS/OS率为21/67个月,和那些第一-,第二-,第三,fourth-,第五-,六线mCRPC患者为11/47,30人中有8人,24人中有7人,19人中有6人,17人中有7人,13个月中有7人,分别。随着收到的新联合治疗线数量的增加,mCRPC的中位OS从26个月(1次全身治疗)改善至52个月(2次或2次以上全身治疗).
■在过去十年中,可以观察到mHSPC和mCRPC患者的治疗模式发生了重大变化,在现实世界的实践中,ADT单一疗法的使用迅速减少。此外,每个治疗线的PFS都显着降低,和OS随着新疗法的实施而增加。
■在现实世界中改善了对转移性激素敏感和去势抵抗前列腺癌的联合疗法的使用,这反映在当代的生存结果中。
UNASSIGNED: With approval of novel systemic therapies within the past decade for metastatic hormone-sensitive (mHSPC) and castration-resistant (mCRPC) prostate cancer, patients may receive several therapy lines. However, the use of these treatments is under an ongoing change. We investigated contemporary treatment trends and progression-free (PFS) and overall (OS) survival of different therapy lines.
UNASSIGNED: Relying on our institutional tertiary-care database, we identified mHSPC and mCRPC patients. The main outcome consisted of treatment changes (estimated annual percentage change [EAPC]) within the past decade, as well as PFS and OS for different mHSPC and mCRPC treatment lines.
UNASSIGNED: In 1098 metastatic patients, the median age was 70 yr with a median of two systemic therapy lines. For first-line mCRPC between 2013 and 2023, androgen deprivation monotherapy (ADT) monotherapy usage decreased significantly from 31% to 0% (EAPC -38.3%, p < 0.001), while the administration of chemotherapy increased from 16.7% to 33.3% (EAPC: +10.1%, p < 0.001). The PFS/OS rates of mHSPC patients was 21/67 mo, and those for first-, second-, third-, fourth-, fifth-, and sixth-line mCRPC patients were 11/47, eight of 30, seven of 24, six of 19, seven of 17, and seven of 13 mo, respectively. With an increased number of new combination therapy lines received, the median OS in mCRPC improved from 26 mo (one systemic treatment) to 52 mo (two or more lines of systemic treatment).
UNASSIGNED: Significant changes in treatment patterns could be observed for mHSPC and mCRPC patients within the past decade, and usage of ADT monotherapy has decreased rapidly in real-world practice. Moreover, PFS decreases significantly with every therapy line, and OS increases with the implementation of new therapies.
UNASSIGNED: Improvements in the real-world setting regarding the usage of combination therapies for metastatic hormone-sensitive and castration-resistant prostate cancer were made, which is reflected in contemporary survival outcomes.